Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials

Beta-adrenergic blocking agents (abbreviated as beta-blockers) have been used for treating various cardiovascular diseases. However, the potential for asthma exacerbation is one of the major adverse effects of beta-blockers. This study aimed to compare the level of risk for an asthma attack in patients receiving various beta-blockers. We searched for randomized controlled trials (RCTs) of either placebo-controlled or active-controlled design. The current network meta-analysis (NMA) was conducted under a frequentist model. The primary outcome was the incidence of asthmatic attack. A total of 24 RCTs were included. Overall NMA revealed that only oral timolol risk ratio (RR) = 3.35 (95% confidence interval (CI) 1.04-10.85) and infusion of propranolol RR = 10.19 (95% CI 1.29-80.41) were associated with significantly higher incidences of asthma attack than the placebo, whereas oral celiprolol RR = 0.39 (95% CI 0.04-4.11), oral celiprolol and propranolol RR = 0.46 (95% CI 0.02-11.65), oral bisoprolol RR = 0.46 (95% CI 0.02-11.65), oral atenolol RR = 0.51 (95% CI 0.20-1.28), infusion of practolol RR = 0.80 (95% CI 0.03-25.14), and infusion of sotalol RR = 0.91 (95% CI 0.08-10.65) were associated with relatively lower incidences of asthma attack than the placebo. In participants with a baseline asthma history, in addition to oral timolol and infusion of propranolol, oral labetalol, oxprenolol, propranolol, and metoprolol exhibited significantly higher incidences of asthma attack than did the placebo. In conclusion, oral timolol and infusion of propranolol were associated with a significantly higher risk of developing an asthma attack in patients, especially in those with a baseline asthma history, and should be avoided in patients who present a risk of asthma.Trial registration: PROSPERO CRD42020190540.